



OPEN ACCESS

APPROVED BY

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Malin Lindstedt
✉ malin.lindstedt@immun.lth.se
Gosse J. Adema
✉ Gosse.Adema@radboudumc.nl
Catarina R. Almeida
✉ cra@ua.pt

[†]These authors have contributed
equally to this work and share
first authorship

RECEIVED 03 December 2024

ACCEPTED 28 January 2025

PUBLISHED 07 February 2025

CITATION

Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, Bækkevold ES, Petitprez F, Lindstedt M, Adema GJ and Almeida CR (2025) Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases. *Front. Immunol.* 16:1538818. doi: 10.3389/fimmu.2025.1538818

COPYRIGHT

© 2025 Reste, Ajazi, Sayi-Yazgan, Jankovic, Bufan, Brandau, Bækkevold, Petitprez, Lindstedt, Adema and Almeida. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases

Mariana Reste^{1†}, Kristi Ajazi^{2†}, Ayca Sayi-Yazgan^{3,4}, Radmila Jankovic⁵, Biljana Bufan⁶, Sven Brandau⁷, Espen S. Bækkevold⁸, Florent Petitprez⁹, Malin Lindstedt^{2*}, Gosse J. Adema^{10*} and Catarina R. Almeida^{1*}

¹Institute of Biomedicine (IBIMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal, ²Department of Immunotechnology, Lund University, Lund, Sweden, ³Department of Molecular Biology and Genetics, Faculty of Science and Letters, Istanbul Technical University, Istanbul, Türkiye, ⁴Department of Life Sciences, Centre for Inflammation Research and Translational Medicine, College of Health and Life Sciences, Brunel University London, Uxbridge, United Kingdom, ⁵Faculty of Medicine, Institute of Pathology, University of Belgrade, Belgrade, Serbia, ⁶Department of Microbiology and Immunology, University of Belgrade - Faculty of Pharmacy, Belgrade, Serbia, ⁷Experimental and Translational Research, Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany, ⁸Department of Pathology, Oslo University Hospital-Rikshospitalet, Oslo, Norway, ⁹Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, United Kingdom, ¹⁰Radiotherapy & Oncolmumonology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands

KEYWORDS

tertiary lymphoid structures (TLS), tertiary lymphoid organs (TLO), dendritic cells (DC), anti-tumor immunity, autoimmunity

A Corrigendum on

[The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases](#)

By Reste M, Ajazi K, Sayi-Yazgan A, Jankovic R, Bufan B, Brandau S, Bækkevold ES, Petitprez F, Lindstedt M, Adema GJ and Almeida CR (2024) *Front. Immunol.* 15:1439413. doi: 10.3389/fimmu.2024.1439413

In the published article, there was an error in the **Funding** statement. The section originally stated that “COST is supported by the EU Framework Program Horizon 2020”, while it should refer to “Horizon Europe”. The correct **Funding** statement appears below.

“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was developed within the scope of projects with references UIDB/04501/2020 and <https://doi.org/10.54499/UIDB/04501/2020>, UIDP/04501/2020 and <https://doi.org/10.54499/UIDP/04501/2020>, 2022.03217.PTDC and DOI 10.54499/2022.03217.PTDC, financially supported by national funds (OE),

through FCT - Fundação para a Ciência e Tecnologia, I.P./MCTES. This work was also supported by the World Scleroderma Foundation and Edit Busch Stiftung (MAPFib). This work has been supported by Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade, Faculty of Medicine No: 451-03-66/2024-03/200110. This work was funded by the Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161. This work was supported by the Wellcome Trust (225021/Z/22/Z). This work was supported by the Swedish Cancer Society (22 2221.Pj.01.H) and Mrs. Berta Kamprad's Cancer Foundation (FBKS-2022-8-368). This work was supported by the Scientific and Technological Research Council of Turkey- TUBITAK (119S447 and 22AG077). This work was also supported by European Cooperation in Science

and Technology (COST) Action CA20117 Mye-InfoBank (www.mye-infobank.eu); COST is supported by the EU Framework Program Horizon Europe.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.